Bain Capital Life Sciences Investors, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Bain Capital Life Sciences Investors, LLC reported 25 stock positions worth $848.7 million. Its top holding was Newamsterdam Pharma (NAMS) at 32.5% of the portfolio, followed by Nuvalent Class A (NUVL, 13.3%) and Pharvaris (PHVS, 7.5%). Compared with Q3 2024, it opened 2 new positions, added to 1 and reduced 5. The biggest buy was Newamsterdam Pharma (NAMS, shares +2%) and the biggest sale Nuvalent Class A (NUVL, shares −46%).
- Most Recent 13F
- Q2 2026
- Location
- Boston, MA
- CIK
- 0001703031
- Portfolio Value
- $848.7M (Q4 2024)
- SEC Filing
- 0000950123-25-002317 ↗ filed Feb 14, 2025
Holdings Value
Holdings 25 stocks · $848.7M
| NAMS Newamsterdam Pharma Co. NV | 32.46% | 10,719,110 | $275.5M | Add +2.3% |
| NUVL Nuvalent Inc. Class A | 13.35% | 1,447,267 | $113.3M | Reduce -46.3% |
| PHVS Pharvaris NV | 7.46% | 3,303,381 | $63.3M | No change |
| IRON Disc Medicine Inc. | 7.35% | 983,500 | $62.4M | Reduce -45.2% |
| DNTH Dianthus Therapeutics Inc. | 6.91% | 2,689,707 | $58.6M | Reduce -10.7% |
| SVRA Savara Inc. | 5.27% | 14,565,457 | $44.7M | No change |
| OLMA Olema Pharmaceuticals Inc. | 5.13% | 7,470,214 | $43.6M | New |
| UPB Upstream Bio Inc. | 4.45% | 2,295,322 | $37.7M | New |
| ANNX Annexon Inc. | 3.17% | 5,249,069 | $26.9M | Reduce -37.9% |
| CDTX Cidara Therapeutics Inc. | 2.23% | 703,080 | $18.9M | No change |
| SLDB Solid Biosciences Inc. | 1.90% | 4,034,582 | $16.1M | No change |
| KYTX Kyverna Therapeutics Inc. | 1.48% | 3,368,370 | $12.6M | No change |
| XFOR X4 Pharmaceuticals Inc. | 1.46% | 16,915,784 | $12.4M | No change |
| MERSANA THERAPEUTICS INC | 1.46% | 8,663,673 | $12.4M | No change |
| TNGX Tango Therapeutics Inc. | 0.99% | 2,712,008 | $8.4M | No change |
| AVIR Atea Pharmaceuticals Inc. | 0.98% | 2,485,638 | $8.3M | No change |
| RPID Rapid Micro Biosystems Inc. Class A | 0.89% | 8,434,560 | $7.6M | No change |
| CABA Cabaletta Bio Inc. | 0.74% | 2,760,888 | $6.3M | No change |
| IPSC Century Therapeutics Inc. | 0.64% | 5,410,361 | $5.5M | No change |
| XLO Xilio Therapeutics Inc. | 0.51% | 4,566,817 | $4.4M | No change |
| CCCC C4 Therapeutics Inc. | 0.47% | 1,111,910 | $4.0M | No change |
| NAUT Nautilus Biotechnology Inc. | 0.35% | 1,759,000 | $3.0M | Reduce -12.1% |
| MRNS Marinus Pharmaceuticals Inc. | 0.17% | 2,693,380 | $1.4M | No change |
| IVVD Invivyd Inc. | 0.09% | 1,799,595 | $797K | No change |
| SYRS Syros Pharmaceuticals Inc. | 0.07% | 2,750,151 | $632K | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $1.4M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | 100,000 | $1.4M | No change |
Total filed on the 13F, all lines: $850.1M.
Portfolio Sells Q3 2024 → Q4 2024
Portfolio Buys Q3 2024 → Q4 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 20 | $1.7B | KLRA, HTFL, NAMS, SVRA, ALKS |
| Q1 2026 | 19 | $1.1B | HTFL, NAMS, OLMA, SVRA, PHVS |
| Q4 2025 | 18 | $1.3B | HTFL, NAMS, OLMA, SVRA, PHVS |
| Q3 2025 | 20 | $1.5B | HTFL, NAMS, CDTX, PHVS, OLMA |
| Q2 2025 | 22 | $798.5M | NAMS, CDTX, NUVL, PHVS, DNTH |
| Q1 2025 | 23 | $675.0M | NAMS, NUVL, PHVS, IRON, DNTH |
| Q4 2024 | 25 | $848.7M | NAMS, NUVL, PHVS, IRON, DNTH |
| Q3 2024 | 23 | $960.5M | NUVL, NAMS, IRON, DNTH, SVRA |
| Q2 2024 | 24 | $910.0M | NUVL, NAMS, IRON, DNTH, PHVS |
| Q1 2024 | 25 | $1.2B | NAMS, NUVL, DNTH, IRON, KYTX |